| scholarly article | Q13442814 |
| P2093 | author name string | Bennett JE | |
| Hospenthal DR | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | 5-fluorocytosine | Q238490 |
| cryptococcosis | Q1470140 | ||
| P304 | page(s) | 260-264 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Flucytosine monotherapy for cryptococcosis. | |
| P478 | volume | 27 |
| Q36201569 | Antifungal combination therapy: clinical potential |
| Q37463223 | Antifungal drug resistance mechanisms. |
| Q34666666 | Antifungal drug resistance: does it matter? |
| Q39751373 | Antifungal resistance and new strategies to control fungal infections |
| Q33975757 | Antifungal susceptibility testing: practical aspects and current challenges |
| Q37048679 | Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact |
| Q73235156 | Chronic Meningitis |
| Q77752654 | Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff |
| Q36018713 | Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. |
| Q34301547 | Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. |
| Q27012487 | Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal |
| Q34923038 | Has antifungal susceptibility testing come of age? |
| Q39064815 | Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. |
| Q33651853 | Overcoming antifungal resistance |
| Q34721673 | Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis |
| Q90578032 | Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update |
| Q38796140 | Systemic Antifungal Agents: Current Status and Projected Future Developments. |
| Q30366117 | Treatment of cryptococcosis in the setting of HIV coinfection. |
| Q28481716 | Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis |
Search more.